Zentalis Pharmaceuticals, Inc. Company Analysis & Research
Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for cancer treatment, with its lead program azenosertib in Phase 3 clinical trials for ovarian cancer and other tumor types. The company targets fundamental cancer biology pathways through its integrated discovery engine approach.
The company is developing azenosertib as a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer. The Phase 2 DENALI trial remains on track with topline data expected by year-end 2026 with potential to support accelerated approval.
Company Overview
Founded: 2014. Headquarters: San Diego, CA, United States. Revenue: $26.9M. Employees: 166. Market Cap: $152M. Ticker: ZNTL (NASDAQ).
Industry
Biotechnology / Oncology
Cyborg Score: 4/10 — Mixed
Early-stage WEE1 inhibitor pure-play with cash runway to late 2027 and potential accelerated approval pathway in platinum-resistant ovarian cancer, but faces binary clinical and regulatory risk.
With a market cap of $152M and trailing 12-month revenue of $26.9M, Zentalis faces typical clinical-stage biotech risks. The company has strong cash reserves of $280.7M providing runway into late 2027, supporting program advancement, but success hinges on DENALI trial outcomes.
Key Strategic Insights for Zentalis Pharmaceuticals, Inc.
- DENALI Phase 2 trial remains on track with topline data expected by year-end 2026 with potential accelerated approval pathway
- Company has $280.7M in cash, providing operational runway into late 2027
- TETON Phase 2 uterine serous carcinoma trial completed enrollment with results planned for H1 2026
- Pipeline includes ZN-c5 (breast cancer), ZN-d5 (lymphoma/leukemia), and ZN-e4 (lung cancer) in Phase 1/2 trials
Recent Developments
- (November 2025) Q3 2025 results: $280.7M cash runway, quarterly operating expenses $33.7M, DENALI Part 2 on track
- (October 2025) Four poster presentations at AACR-NCI-EORTC conference on azenosertib clinical data and biomarker findings
- (September 2025) Morgan Stanley Global Healthcare Conference presentation on development strategy
Competitors & Competitive Landscape
- ORIC Pharmaceuticals, Inc. — Oncology biotech developing targeted cancer therapies
- Prelude Therapeutics Incorporated — Clinical-stage oncology company
- HOOKIPA Pharma Inc. — Immunotherapy company
Competitors include ORIC Pharmaceuticals, Prelude Therapeutics, Hookipa Pharma, Ayala Pharmaceuticals, and Enliven Therapeutics. Zentalis differentiates through its WEE1 inhibitor approach and biomarker-driven patient selection strategy targeting Cyclin E1-positive populations in platinum-resistant ovarian cancer.
More Company Research
Green Landscaping Group AB (publ) City Cement Company SD Biosensor, Inc. Novavax, Inc. Enovis Corporation DOF Group ASA Tohoku Electric Power Company, Incorporated Charoen Pokphand Foods Public Company Limited Floor & Decor Holdings, Inc. Adani Energy Solutions Limited Helvetia Baloise Holding Ltd General Dynamics Corporation Cherry SE Villars Holding S.A. Gévelot SAFull Company Research Reports
Looking for a more in-depth analysis of Zentalis Pharmaceuticals, Inc.? AskCyborg's Company Research section contains full AI-generated reports with detailed financials, strategic analysis, and Cyborg Score ratings. Browse the complete company research library or explore industry research reports.
AskCyborg provides AI-powered company research and analysis. Visit AskCyborg for full reports, Cyborg Score ratings, and analyst podcasts.